Holen Sie sich die Stockscreener-App
51.84
2.49%
1.26
Schlusskurs vom Vortag:
$50.58
Offen:
$51.46
24-Stunden-Volumen:
812.83K
Relative Volume:
0.71
Marktkapitalisierung:
$3.95B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.22M
KGV:
-13.71
EPS:
-3.78
Netto-Cashflow:
$-212.64M
1W Leistung:
+2.61%
1M Leistung:
+102.50%
6M Leistung:
+96.74%
1J Leistung:
+115.64%
1-Tages-Spanne:
$51.09
$52.74
1-Wochen-Bereich:
$48.70
$52.74
52-Wochen-Spanne:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
51.84 | 3.95B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Akero Therapeutics chief development officer sells $498k in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Growth in Short Interest - MarketBeat
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ) - TradingView
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 - Insider Monkey
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Average PT from Brokerages - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Increase in Short Interest - Defense World
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $75.86 - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares - MarketBeat
(AKRO) Technical Pivots with Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - Markets Insider
Is Akero Therapeutics Inc (NASDAQ: AKRO) A Good Pick For New Investors Now? - Stocks Register
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by abrdn plc - MarketBeat
Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - Markets Insider
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 18,750 Shares - MarketBeat
Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing - Marketscreener.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Acquires 200,000 Shares - MarketBeat
Akero Therapeutics CEO Cheng Andrew Sells 30,000 Shares - TradingView
Investigation announced for Long-Term Investors in shares - openPR
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Financial Analysis: Akero Therapeutics Inc (AKRO)’s Ratios Unveil Key Insights - The Dwinnex
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider
Akero Therapeutics' chief scientific officer sells $1.06 million in stock - MSN
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN
Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - AOL
Akero Therapeutics' chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com South Africa
Akero Therapeutics’ chief scientific officer sells $1.06 million in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics Stock Doubles on Liver Data - MSN
Akero Therapeutics director Graham Walmsley acquires $9.6 million in stock By Investing.com - Investing.com Australia
Akero Therapeutics' Chief Scientific Officer Sells Shares - TradingView
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock - MSN
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akero Therapeutics Inc-Aktie (AKRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yale Catriona | Chief Development Officer |
Feb 18 '25 |
Sale |
49.87 |
10,000 |
498,660 |
95,648 |
| Cheng Andrew | President and CEO |
Feb 10 '25 |
Sale |
52.73 |
30,000 |
1,581,994 |
686,062 |
| Graham G. Walmsley | Director |
Jan 30 '25 |
Buy |
48.00 |
200,000 |
9,600,000 |
1,000,000 |
| Rolph Timothy | Chief Scientific Officer |
Feb 05 '25 |
Option Exercise |
21.10 |
18,750 |
395,625 |
188,987 |
| Rolph Timothy | Chief Scientific Officer |
Feb 05 '25 |
Sale |
56.51 |
18,750 |
1,059,630 |
170,237 |
| Young Jonathan | Chief Operating Officer |
Feb 03 '25 |
Sale |
53.81 |
10,000 |
538,061 |
251,147 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Option Exercise |
10.48 |
53,590 |
561,807 |
149,238 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Sale |
56.25 |
53,590 |
3,014,216 |
95,648 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Option Exercise |
21.10 |
49,074 |
1,035,461 |
144,722 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Sale |
55.72 |
49,074 |
2,734,212 |
95,648 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):